Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiov...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839058/ https://www.ncbi.nlm.nih.gov/pubmed/27071968 http://dx.doi.org/10.1007/s00059-016-4427-3 |